Functional imaging using diffuse optical spectroscopy of neoadjuvant chemotherapy response in women with locally advanced breast cancer

Clinical Cancer Research

Volumn 16, Issue 9, 2010, Pages 2605-2614

  Soliman, Hany ^a,b   Gunasekara, Anoma ^b   Rycroft, Mary ^b   Zubovits, Judit ^a   Dent, Rebecca ^b   Spayne, Jacqueline ^a   Yaffe, Martin J ^a,b   Czarnota, Gregory J ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DEOXYHEMOGLOBIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; OXYHEMOGLOBIN; PAMIDRONIC ACID; SUNITINIB; TRASTUZUMAB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; FEMALE; HUMAN; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SPECTROSCOPY; TREATMENT RESPONSE; TUMOR VOLUME; WATER CONTENT;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DIAGNOSTIC IMAGING; FEMALE; HEMOGLOBINS; HUMANS; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOADJUVANT THERAPY; OXYHEMOGLOBINS; PROGNOSIS; SCATTERING, RADIATION; SPECTROSCOPY, NEAR-INFRARED; TIME FACTORS; TOMOGRAPHY; TREATMENT OUTCOME; WATER;

EID: 77951707744     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1510     Document Type: Article

References (43)

1. American Cancer Society. Breast cancer facts and figures 2007-2008. Atlanta: American Cancer Society, Inc.
2. Canadian Cancer Society/National Cancer Institute of Canada. Canadian cancer statistics 2007. Toronto: Canadian Cancer Society/National Cancer Institute of Canada; 2007.
3. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Drucker MJ, Livingston RB. Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography. Cancer 1999;85: 2410-2423
4. Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002;20:3628-3636 (Pubitemid 34983222)
5. Therasse P, Mauriac L, Welnicka-Jaskiewicz M, et al. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J Clin Oncol 2003;21:843-850 (Pubitemid 46606444)
6. Kuerer H, Newman L, Smith T, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-469 (Pubitemid 29075229)
7. Chatuverdi S, McLaren C, Schofield AC, et al. Patterns of local and distant disease relapse in patients with breast cancer treated with primary chemotherapy: do patients with a complete pathological response differ from those with residual tumor in the breast? Breast Cancer Res Treat 2005;93:151-158
8. Guarneri V, Broglio K, Kau SW, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006;24: 1037-1044 (Pubitemid 46638799)
9. Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 1995;180:297-306.
10. Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 1986;46:2578-2581
11. Machiavelli MR, Romero AO, Perez JE, et al. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am 1998;4:125-131 (Pubitemid 29090716)
12. Carlson RW, Favret AM. Multidisciplinary management of locally advanced breast cancer. Breast J 1999;5:303-307 (Pubitemid 29483453)
13. Nelson TR, Cervino LI, Boone JM, Lindfors KK. Classification of breast computed tomography data. Med Phys 2008;35:1078-1086
14. Segel MC, Paulus DD, Hortobagyi GN. Advanced primary breast cancer: assessment at mammography of response to induction chemotherapy. Radiology 1988;169:49-54.
15. Moskovic EC, Mansi JL, King DM, Murch CR, Smith IE. Mammography in the assessment of response to medical treatment of large primary breast cancer. Clin Radiol 1993;47:339-344
16. Vinnicombe SJ, MacVicar AD, Guy RL, et al. Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation. Radiology 1996;198:333-340 (Pubitemid 26036832)
17. Yeh E, Slanetz P, Kopans DB, et al. Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. Am J Roentgenol 2005;184:868-877 (Pubitemid 43899515)
18. Cutler M. Transillumination as aid in the diagnosis of breast lesions. Surg Gynecol Obstet 1929;48:721-729
19. Ntziachristos V, Chance B. Probing physiology and molecular function using optical imaging: applications to breast cancer. Breast Cancer Res 2001;3:41-46 (Pubitemid 32223652)
20. Leff DR, Warren OJ, Enfield LC, et al. Diffuse optical imaging of the healthy and diseased breast: a systemic review. Breast Cancer Res Treat 2008;108:9-22. (Pubitemid 351623242)
21. Tromberg BJ, Shah N, Lanning R, et al. Non-invasive in vivo characterization of breast tumors using photon migration spectroscopy. Neoplasia 2000;2:26-40. (Pubitemid 30123178)
22. Cerussi A, Hsiang D, Shah N, et al. Predicting response to breast cancer neoadjuvant chemotherapy using diffuse optical spectroscopy. Proc Natl Acad Sci U S A 2007;104:4014-4019 (Pubitemid 47181570)
23. Zhu Q, Kurtzma SH, Hegde P, et al. Utilizing optical tomography with ultrasound localization to image heterogeneous hemoglobin distribution in large breast cancers. Neoplasia 2005;7: 263-270 (Pubitemid 40411638)
24. Jakubowski DB, Cerussi AE, Bevilacqua F, et al. Monitoring neoadjuvant chemotherapy in breast cancer using quantitative diffuse optical spectroscopy: a case study. J Biomed Opt 2004;9: 230-238
25. Choe R, Corlu A, Lee K, et al. Diffuse optical tomography of breast cancer during neoadjuvant chemotherapy: a case study with comparison to MRI. Med Phys 2005;32:1128-1139 (Pubitemid 40586797)
26. Shah N, Gibbs J, Wolverton D, Cerussi A, Hylton N, Tromberg BJ. Combined diffuse optical spectroscopy and contrast-enhanced magnetic resonance imaging for monitoring breast cancer neo-adjuvant chemotherapy: a case study. J Biomed Opt 2005;10: 051503. (Pubitemid 44256004)
27. Clarke GM, Eidt S, Sun L, Mawdsley GE, Zubovits JT, Yaffe MJ. Whole-specimen histopathology: a method to produce whole-mount breast serial section for 3D digital histopathology imaging. Histopathology 2007;50:232-242 (Pubitemid 46046392)
28. Intes X, Djeziri S, Ichalalene Z, et al. Time-domain optical mammography SoftScan: initial results on detection and characterization of breast tumors. Proc SPIE 2004;5578:188-197 (Pubitemid 40948755)
29. Kaufmann M, von Minckwitz G, Bear HD, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 2007;18:1927-1934.
30. Ring AE, Smith IE, Ashley S, Fullford LG, Lakhani SR. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer 2004;91:2012-2017 (Pubitemid 40128767)
31. Colleoni M, Viale G, Zarieh D, et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 2004; 10:6622-6628 (Pubitemid 39346559)
32. Hennessy BT, Hortobagyi GN, Rouzier R, et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 2005;23:9304-9311 (Pubitemid 46260188)
33. Wenzel C, Bartsch R, Hussian D, et al. Invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF. Breast Cancer Res Treat 2007;104:109-114 (Pubitemid 46976638)
34. Tubiana-Hulin M, Stevens D, Lasry S, et al. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Ann Oncol 2006;17: 1228-1233 (Pubitemid 44288213)
35. Cristofanilli M, Gonzalez-Angulo A, Sneige N, et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 2005;23:41-48 (Pubitemid 41702621)
36. Adler LP, Crowe JP, Al-Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-Dglucose PET. Radiology 1993;187:743-750
37. Nieweg OE, Kim EE, Wong WH, et al. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 1993;71:3920-3925 (Pubitemid 23172970)
38. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993; 11:2101-2111 (Pubitemid 23332245)
39. Jansson T, Westlin JE, Ahlstrom H, et al. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol 1995;13:1470-1477
40. 18F] FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy. Ann Oncol 2004;15:1352-1357
41. Padhani AR, Husband JE. Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. Clin Radiol 2001;56:607-620
42. Hylton N. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol 2006;24:3293-3298 (Pubitemid 46622069)
43. Brindle K. New approaches for imaging tumor responses to treatment. Nat Rev Cancer 2008;8:94-107. (Pubitemid 351161320)